

CLINICAL PRACTICE

Asthma in Pregnancy

Michael Schatz, M.D., and Mitchell P. Dombrowski, M.D.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors' clinical recommendations.

A 23-year-old nonsmoking woman (gravida 1, para 0) presents at 11 weeks' gestation with an 8-year history of asthma, which has worsened over the past year. She reports asthma symptoms requiring albuterol two or three times per day and interfering with sleep two or three nights per week. A corticosteroid inhaler was prescribed before pregnancy, but she has been afraid to use it. Cleaning her house triggers asthma, and she has had a cat at home for 1 year. Her forced expiratory volume in 1 second (FEV₁) is 75% of the predicted value; it increases to 88% of the predicted value after administration of albuterol. How should her case be managed?

THE CLINICAL PROBLEM

From the Department of Allergy, Kaiser Permanente Medical Center, San Diego, CA (M.S.); and the Department of Obstetrics and Gynecology, St. John Hospital, and Wayne State University Medical Center (M.P.D.) — both in Detroit. Address reprint requests to Dr. Schatz at the Department of Allergy, Kaiser Permanente Medical Center, 7060 Clairemont Mesa Blvd., San Diego, CA 92111, or at michael.x.schatz@kp.org.

N Engl J Med 2009;360:1862-9.

Copyright © 2009 Massachusetts Medical Society.



An audio version
of this article
is available at
NEJM.org

Asthma is probably the most common potentially serious medical problem that occurs during pregnancy, and approximately 8% of pregnant women reported current asthma in recent national surveys.¹ In several studies, even after adjustment for potential confounders, women with asthma have been reported to have higher risks of several complications of pregnancy, including preeclampsia,²⁻⁷ preterm birth,^{2-4,6} infants with low birth weight or intrauterine growth restriction,^{2-4,6,7} infants with congenital malformations,^{3,8,9} and perinatal death^{2,4,10} than women without a history of asthma. Residual confounding¹¹ or common pathogenetic factors¹²⁻¹⁴ may explain some of these associations. Nevertheless, observational data showing strong associations between poor asthma control during pregnancy (as evidenced by symptoms, impaired pulmonary function, or exacerbations) and these increased risks¹⁵⁻¹⁹ suggest that better asthma control may improve pregnancy outcomes. Treatment also may reduce serious risks to the mother resulting from uncontrolled asthma, including death. However, the choice among medications must take into account their potential adverse effects on the fetus.

In addition to the effect of maternal asthma on pregnancy outcomes, pregnancy may affect the course of asthma. The severity of asthma may improve, worsen, or remain unchanged during pregnancy^{20,21}; the mechanisms underlying changes in the severity of asthma during pregnancy remain undefined.

STRATEGIES AND EVIDENCE

DIAGNOSIS AND EVALUATION

The diagnosis of asthma is usually straightforward, since most patients have a known history of asthma antedating pregnancy. However, diagnostic testing is warranted in patients whose clinical picture or response to therapy is atypical or who present with respiratory symptoms during pregnancy in the absence of a history of asthma. The most common alternative diagnosis is dyspnea of pregnancy, which is not associated with cough, wheezing, chest tightness, or airway obstruction. Other po-

tential diagnoses include cough due to reflux or postnasal drip, bronchitis, laryngeal dysfunction, hyperventilation, pulmonary edema, and pulmonary embolism.^{22,23} The demonstration of a reduced FEV₁ or ratio of FEV₁ to forced vital capacity with a 12% or greater improvement in FEV₁ after the administration of inhaled albuterol confirms a diagnosis of asthma in pregnancy.^{23,24} Methacholine testing, which is used to confirm bronchial hyperreactivity in patients with normal pulmonary function, is contraindicated during pregnancy because of the lack of data on the safety of such testing in pregnant patients. Thus, women with a clinical picture that is consistent with new-onset asthma in whom the diagnosis is not confirmed on the basis of testing for reversibility of impairment in pulmonary function should be treated for asthma until methacholine testing can be performed post partum if indicated.²³ Exhaled nitric oxide has not been studied as a diagnostic measure of asthma in pregnant women.

Patients with persistent asthma who have not previously been tested for allergies should undergo blood testing for specific IgE antibodies to allergens such as dust mites, cockroaches, mold spores, and pets. Skin tests are not generally recommended during pregnancy because skin testing with potent antigens may be associated with systemic reactions.

Current asthma control should be assessed according to the frequency and severity of symptoms (including their interference with sleep and normal activity), the frequency of use of rescue therapy, the history of exacerbations requiring the use of systemic corticosteroids, and the results of pulmonary-function tests (Table 1). Spirometry is the preferred method of assessing pulmonary function, but peak flow measurement is an acceptable alternative. FEV₁ and peak flow rates do not change substantially as a result of pregnancy,²³ so these measures can be used for assessing asthma control in patients who are pregnant just as they are in patients who are not pregnant. Patients who have asthma that is well controlled and who are not receiving controller medications can be classified as having intermittent rather than persistent asthma.

Women who have previously received prescriptions for asthma medications should be asked about their use in order to classify their current level of therapy (according to a stepped-care approach, with step 1 indicating no treatment and

step 6 indicating the most aggressive treatment) (Table 2) and to assess potential problems with and barriers to adherence. Adherence to treatment with inhaled corticosteroids has been reported to be poor in many studies. For example, the reported adherence rate was approximately 50% in one study involving adults with asthma; decreased adherence was associated with an increased frequency of asthma exacerbations.²⁶ Women with asthma have been reported to decrease their use of inhaled corticosteroids during early pregnancy, as compared with their use of these agents in the 20 weeks before their last menstrual period²⁷; this may be due to their reported concern regarding the safety of inhaled corticosteroids during pregnancy.²⁸ Moreover, a substantial proportion of asthmatic exacerbations during pregnancy have been associated with nonadherence to treatment with inhaled corticosteroids.²⁹ In addition to assessing adherence, asking about past medications and their effectiveness and any side effects can help to guide subsequent management decisions.

MANAGEMENT OF ASTHMA

All patients should be educated regarding the relationship between asthma and pregnancy, and they should be taught about self-treatment, including inhaler techniques, adherence to medication, and control of potential environmental triggers (Table 3). The appropriate management of common coexisting conditions that can aggravate asthma, such as rhinitis, sinusitis, and gastroesophageal reflux, can improve asthma control. Women who smoke must be informed of the potential adverse effects of smoking on the fetus, which may add to the fetal effects of uncontrolled asthma,¹⁵ and should be strongly encouraged to quit. Advice on environmental control measures for reducing exposure to allergens can be provided on the basis of the results of allergy testing (Table 4).

Medications for asthma are divided into long-term controller medications that prevent the manifestations of asthma (inhaled corticosteroids, long-acting β -agonists, leukotriene modifiers, cromolyn, and theophylline) (Table 5) and rescue therapy that provides quick relief of symptoms (primarily short-acting inhaled β -agonists). In studies involving patients who were not pregnant, inhaled corticosteroids were the most effective controller medications in terms of reducing symptoms and exacerbations and improving pulmonary function, and all controller medications have been

Table 1. Assessment of Asthma Control in Pregnant Women.*

| Variable | Well-Controlled Asthma | Asthma Not Well Controlled | Very Poorly Controlled Asthma |
|---|------------------------|----------------------------|-------------------------------|
| Frequency of symptoms | ≤2 days/wk | >2 days/wk | Throughout the day |
| Frequency of nighttime awakening | ≤2 times/mo | 1–3 times/wk | ≥4 times/wk |
| Interference with normal activity | None | Some | Extreme |
| Use of short-acting β -agonist for symptom control | ≤2 days/wk | >2 days/wk | Several times/day |
| FEV ₁ or peak flow (% of the predicted or personal best value) | >80 | 60–80 | <60 |
| Exacerbations requiring use of systemic corticosteroid (no.) | 0–1 in past 12 mo | ≥2 in past 12 mo | |

* Data are from the National Asthma Education and Prevention Program.²⁴ The level of control is based on the most severe category. The frequency and effect of symptoms should be assessed according to the patient's recall of the previous 2 to 4 weeks. FEV₁ denotes forced expiratory volume in 1 second.

shown to improve these outcomes better than placebo.²⁴ Long-acting β -agonists have been shown to be more effective than leukotriene-receptor antagonists or theophylline as add-on therapy to inhaled corticosteroids.²⁴ Evidence of the efficacy of these drugs during pregnancy is largely extrapolated from studies involving patients who were not pregnant. To our knowledge, only two randomized, controlled trials specifically involving pregnant patients with asthma have been conducted. These studies showed that inhaled beclomethasone is more effective than theophylline in improving pulmonary function³⁰ and that prescribing inhaled beclomethasone in addition to oral corticosteroids and inhaled β -agonists at the time of discharge after hospitalization for asthma results in fewer subsequent readmissions for asthma as compared with oral corticosteroids and inhaled β -agonists alone.³¹

Although data on adverse effects of asthma medications in pregnancy are of necessity largely observational, most of the findings are reassuring. Many studies have shown no increased perinatal risks (including preeclampsia, preterm birth, low birth weight, and congenital malformations) associated with the use of inhaled β -agonists or inhaled corticosteroids^{32–38} in women who were exposed to these agents; one study involved 2968 women.³⁸ Among the drugs for which reassuring data on use in pregnancy are available, albuterol is the inhaled β -agonist that has been studied most extensively,³³ and budesonide is the most extensively studied inhaled corticosteroid.^{37,38}

In one recent case-control study, the use of bronchodilators during pregnancy was associated

with an increased risk of gastroschisis among infants (odds ratio, 2.1; 95% confidence interval [CI], 1.2 to 3.6).³⁹ Also, in a recent cohort study involving 4558 women, exposure to bronchodilators during pregnancy was associated with an increased risk of cardiac defects among infants (odds ratio, 1.4; 95% CI, 1.1 to 1.7).⁹ However, the reported increased risk of congenital malformations among infants whose mothers had asthma with exacerbations as compared with those who did not have exacerbations⁴⁰ suggests that these associations with bronchodilators may be confounded by indication (i.e., underlying exacerbations may lead to the need for bronchodilators) or other factors, such as obesity or lower household socioeconomic status, that may be associated with both more severe asthma and congenital malformations.^{41,42}

The use of oral corticosteroids among pregnant women with asthma has been associated with increased risks of preeclampsia and prematurity among their offspring, as compared with the use of other asthma medications. Although these associations have remained significant after adjustment for several potential confounders,^{32,33} residual confounding by greater disease severity and poorer asthma control in these studies cannot be ruled out.

Reassuring data on the use of cromolyn and theophylline in pregnant women have been published.²⁵ Data on the use of leukotriene-receptor antagonists during pregnancy are more limited; we are aware of only one published study, involving 96 patients, that supports their safety during pregnancy.⁴³ Data are lacking regarding the safety

of long-acting β -agonists during pregnancy, although the inhalational route and the generally reassuring data on short-acting β -agonists suggest that these agents are probably safe.²⁵ A possible association between long-acting β -agonists and an increased risk of severe and even fatal asthma exacerbations has been observed in patients who were not pregnant. Although the data are sparse, expert panels suggest that the benefits of the use of long-acting β -agonists appear to outweigh the risks as long as they are used concurrently with inhaled corticosteroids.^{44,45} Overall, the risks associated with asthma medications in current use are considered to be definitely lower than the risks associated with uncontrolled asthma.

It is appropriate for pregnant patients with well-controlled asthma to continue taking their medications. In patients who are not pregnant and who have asthma that has been controlled for at least 3 months with the use of controller medications, guidelines recommend consideration of a step down in therapy²⁴; however, it may be prudent to maintain the current level of therapy during pregnancy in order to reduce the risk of a loss of control. For patients at step 5 or 6 (Table 2), a careful reduction in therapy may be considered if the previous course of asthma and the course during pregnancy suggest that a reduction is likely to be tolerated without a loss of control.

Therapy should be increased by one step (Table 2) in patients with asthma that is not well controlled despite consideration of the nonpharmacologic strategies described above. A two-step increase, a course of oral corticosteroids, or both should be recommended for women with asthma that is very poorly controlled.

Monthly visits to assess asthma control are recommended for women who require controller therapy during pregnancy. This assessment may be performed as part of routine obstetrical visits or by the primary care physician or asthma specialist who is managing the patient's asthma. Patients with very poorly controlled asthma should be seen every 1 to 2 weeks until control is achieved.

ASTHMA EXACERBATIONS

An asthma exacerbation in a pregnant patient, as in any adult, should be managed with inhaled β -agonists, inhaled anticholinergic drugs, and systemic corticosteroids.^{23,24} Maintenance of an arterial oxygen saturation of at least 95%, mea-

Table 2. Steps of Asthma Therapy during Pregnancy.*

| Step | Preferred Controller Medication | Alternative Controller Medication |
|------|---|---|
| 1 | None | — |
| 2 | Low-dose inhaled corticosteroid | LTRA, theophylline, or cromolyn |
| 3 | Medium-dose inhaled corticosteroid | Low-dose inhaled corticosteroid plus LABA, LTRA, or theophylline |
| 4 | Medium-dose inhaled corticosteroid plus LABA | Medium-dose inhaled corticosteroid plus either LTRA or theophylline |
| 5 | High-dose inhaled corticosteroid plus LABA | — |
| 6 | High-dose inhaled corticosteroid plus LABA plus oral prednisone | — |

* Data are from the National Asthma Education and Prevention Program.^{24,25} We have modified step 3 to reflect the choice of a medium-dose inhaled corticosteroid over a low-dose inhaled corticosteroid plus a long-acting β -agonist (LABA) because of the lack of safety data on the use of LABA during pregnancy. LTRA denotes leukotriene-receptor antagonist.

Table 3. Patient Education for Self-Treatment of Asthma during Pregnancy.

| Subject | Recommendation |
|----------------------------|---|
| General information | Provide basic information about asthma and relationship between asthma and pregnancy |
| Use of inhaler device | Demonstrate proper technique for specific device and ask patient to perform the technique; demonstrate use of spacer device for metered-dose inhaler if patient's inhaler technique is sub-optimal |
| Adherence to treatment | Discuss self-reported adherence to treatment with controller medication and, if needed, address barriers to optimal adherence (e.g., cost, convenience, concern about side effects) |
| Self-treatment action plan | Provide schedule for maintenance medication and doses of rescue therapy for increased symptoms; explain when and how to increase controller medication and when and how to use prednisone (for patients with previous prednisone use or poorly controlled asthma); explain how to recognize a severe exacerbation and when and how to seek urgent or emergency care |

sured by means of pulse oximetry, is recommended to ensure sufficient oxygenation in both the mother and the fetus.²² Assessment of the fetus during an acute asthma episode depends on the stage of the pregnancy, but continuous electronic fetal monitoring, a biophysical profile, or both should be considered if the fetus has reached the stage of viability.²³ A biophysical profile includes a nonstress test for a reactive fetal heart rate, ul-

Table 4. Environmental Control Measures to Reduce Exposure to Allergens.*

| Allergen | Instructions | Level of Evidence |
|---------------|---|---|
| Animal dander | Remove pet from house; if removal not acceptable, keep pet out of bedroom | Consensus judgment |
| Dust mites | Encase pillow and mattress with impermeable covers; wash sheets and blankets weekly in hot water | Data from several randomized, controlled trials |
| Cockroaches | Do not leave food or garbage exposed; use poison baits or traps rather than chemical agents, which can aggravate asthma | Few randomized, controlled trials |

* Data are from the National Asthma Education and Prevention Program.²⁴ These data are not specific to pregnancy.

trasonographic measurement of amniotic-fluid volume, observation of the presence or absence of fetal breathing movements, and observation of gross body movements and fetal tone. If oxygen saturation remains below a level of at least 95% (as measured by means of pulse oximetry) while the patient is breathing ambient air, if FEV₁ or peak expiratory flow remains below 70% of the predicted value, or if there is evidence of fetal compromise, the patient should be hospitalized, with careful medical and obstetrical surveillance.^{22,23} This pulmonary-function criterion, which is based on general recommendations for asthmatic exacerbations, is supported by some observational data,²⁴ although we are aware of no specific data in pregnant women with asthma.

OBSTETRICAL CARE

In general, data are lacking on the optimal obstetrical care of patients with asthma, and recommendations are based on extrapolation of data from other clinical settings and expert opinion. Women with asthma that is not well controlled may benefit from increased fetal surveillance. Ultrasonographic examinations can be helpful to establish accurate pregnancy dating and monitor fetal growth, which (as described above) can be affected by uncontrolled asthma. Assessment of fetal well-being, usually by means of nonstress testing, should be considered, starting at 32 weeks' gestation.²³

Adequate hydration and analgesia should be maintained during labor and delivery; analgesia

should not compromise the patient's respiratory status, and insufficient pain control could trigger bronchospasm. Use of asthma medications should be continued during labor and delivery. It is commonly recommended that women who are currently taking systemic corticosteroids or who have received several short courses of systemic corticosteroids during pregnancy receive intravenous corticosteroids (e.g., hydrocortisone at a dose of 100 mg every 8 hours) during labor and for 24 hours after delivery in order to prevent adrenal crisis.²² Prostaglandin E₁ or E₂ can be used for cervical ripening, management of spontaneous or induced abortions, or postpartum hemorrhage, although the patient's respiratory status should be monitored for bronchospasm.⁴⁶ In contrast, carboprost (15-methyl prostaglandin F_{2α}) and ergonovine may trigger bronchospasm and should be avoided, if possible.²² If tocolysis is required, magnesium sulfate and terbutaline are preferable because they are bronchodilators; in contrast, indomethacin can induce bronchospasm in a patient with aspirin-sensitive asthma.²²

Cesarean delivery is rarely required in patients with an acute asthmatic exacerbation; maternal and fetal compromise usually responds to aggressive medical management. Lumbar anesthesia can reduce oxygen consumption and minute ventilation during labor.⁴⁷ The obstetrician, anesthesiologist, and pediatrician should coordinate intrapartum and postpartum care. In general, only small amounts of the asthma medications listed in Table 5 enter breast milk; none are a contraindication to breast-feeding.^{23,25}

AREAS OF UNCERTAINTY

The mechanisms linking poorly controlled asthma to adverse perinatal outcomes remain unclear. It is not possible in observational studies to definitely distinguish the potential contributions of increased asthma severity and poor asthma control from the potential effects of medications used in more severe cases. Because of the ethical issues raised, controlled trials cannot be performed to determine the effects of asthma control, as compared with lack of control, on perinatal outcomes. Controlled trials are unlikely to be large enough to determine the absolute safety of various asthma medications during pregnancy, especially with regard to uncommon outcomes such as specific congenital malformations.

Table 5. Controller Medications for the Management of Asthma during Pregnancy.*

| Drug | Usual Dose | Potential Adverse Effects | FDA Pregnancy Class† | Recommended Use‡ |
|----------------------------------|---|---|----------------------|---|
| Inhaled corticosteroids | | | | Preferred controller therapy |
| Budesonide | Low: 180–600 µg/day; medium: >600–1200 µg/day; high: >1200 µg/day | Cough, dysphonia, thrush; potential systemic effects at high doses; local side effects decreased with valved holding chamber (spacer) | B§ | Preferred inhaled corticosteroid because of more reassuring data in humans |
| Beclomethasone | Low: 80–240 µg/day; medium: >240–480 µg/day; high: >480 µg/day | for metered-dose inhalers that are not breath-actuated | C¶ | |
| Fluticasone | Low: 100–300 µg/day; medium: >300–500 µg/day; high: >500 µg/day | and with mouth washing and spitting after inhalation | C¶ | |
| Long-acting β-agonists | | Tachycardia, skeletal-muscle tremor, hypokalemia; possible increase in risk of severe, life-threatening, or fatal exacerbation | | Preferred add-on therapy to medium- or high-dose inhaled corticosteroids |
| Salmeterol | 1 blister twice daily | | C¶ | Alternative for mild asthma or as add-on therapy to inhaled corticosteroids, especially in patients with good response before pregnancy |
| Formoterol | 1 capsule twice daily | | C¶ | |
| Leukotriene-receptor antagonists | | | | |
| Montelukast | 10 mg daily | No major adverse effects identified | B | Alternative for mild asthma |
| Zafirlukast | 20 mg twice daily | Cases of hepatitis reported | B | |
| Cromolyn | 2 puffs four times daily | Cough | B | |
| Theophylline | 400–600 mg/day (based on theophylline level) | Insomnia, gastric upset, aggravation of gastroesophageal reflux | C¶ | Alternative for mild asthma or as add-on therapy to inhaled corticosteroids |

* Data are from the National Asthma Education and Prevention Program.^{24,25} FDA denotes Food and Drug Administration.

† A pregnancy rating of B indicates that reassuring data from studies in animals or humans have been submitted to the FDA, and a rating of C that a risk to the fetus cannot be ruled out on the basis of submitted data.

‡ Data are based on relative efficacy in all patients with asthma and safety data in pregnant women.

§ Data are based on nonreassuring studies of systemic administration in animals, but reassuring data in humans have been submitted to the FDA.

¶ Data are based on nonreassuring studies of systemic administration in animals, and no data in humans have been submitted to the FDA.

|| Data are based on reassuring studies in animals, but no data in humans have been submitted to the FDA.

GUIDELINES

National guidelines for the management of asthma during pregnancy were most recently updated in 2004,²⁵ and general guidelines for the management of asthma in all patients were updated in 2007.²⁴ The American College of Obstetricians and Gynecologists published guidelines on the clinical management of asthma during pregnancy in 2008.²³ The recommendations in this article are consistent with these guidelines.

CONCLUSIONS AND RECOMMENDATIONS

Although uncontrolled asthma may increase the risk of adverse perinatal outcomes, women with well-controlled asthma in pregnancy generally have good pregnancy outcomes.^{48–50} The patient described in the vignette has poorly controlled asthma, as evidenced by daily symptoms and daily use of rescue therapy, asthma that interferes with sleep more than once a week, and an FEV₁ of less than

80% of the predicted value. This patient should be educated regarding the potential risks of uncontrolled asthma for herself and her pregnancy. We would recommend testing for sensitivity to mites, cat dander, and cockroach allergens and initiate medium-dose inhaled corticosteroids (a two-step therapy increase). We would choose inhaled budesonide (180 μ g per puff, two puffs twice a day) over other inhaled corticosteroids because more safety data are available on the use of this drug during the gestational period. The patient should also be instructed in the use of an optimal inhaler technique, and she should be giv-

en a personalized self-treatment action plan for asthma that includes instructions regarding the maintenance medication schedule, doses of rescue therapy for increased symptoms, and when and how to seek urgent or emergency care. We would recommend follow-up every 1 to 2 weeks initially to ensure that asthma control is achieved and then, once the patient's condition is stable, at least monthly throughout the pregnancy.

Dr. Schatz reports receiving consulting fees from Glaxo-SmithKline and grant support from Aerocrine, Genentech, GlaxoSmithKline, and Merck. No other potential conflict of interest relevant to this article was reported.

REFERENCES

1. Kwon HL, Triche EW, Belanger K, Bracken MB. The epidemiology of asthma during pregnancy: prevalence, diagnosis, and symptoms. *Immunol Allergy Clin North Am* 2006;26:29-62.
2. Bahna SL, Bjerkedal T. The course and outcome of pregnancy in women with bronchial asthma. *Acta Allergol* 1972;27:397-406.
3. Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. *Am J Respir Crit Care Med* 1998;158:1091-5.
4. Källén SL, Rydhstroem H, Aberg A. Asthma during pregnancy — a population based study. *Eur J Epidemiol* 2000;16:167-71.
5. Wen SW, Demissie K, Liu S. Adverse outcomes in pregnancies of asthmatic women: results from a Canadian population. *Ann Epidemiol* 2001;11:7-12.
6. Liu S, Wen SW, Demissie K, Marcoux S, Kramer MS. Maternal asthma and pregnancy outcomes: a retrospective cohort study. *Am J Obstet Gynecol* 2001;184:90-6.
7. Enriquez R, Griffin MR, Carroll KN, et al. Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. *J Allergy Clin Immunol* 2007;120:625-30.
8. Tamási L, Somoskövi A, Müller V, et al. A population-based case-control study on the effect of bronchial asthma during pregnancy for congenital abnormalities in the offspring. *J Asthma* 2006;43:81-6.
9. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. *Eur J Clin Pharmacol* 2007;63:383-8.
10. Breton MC, Beauchesne M-F, Lemièrre C, Rey E, Forget A, Blais L. Risk of perinatal mortality associated with asthma during pregnancy. *Thorax* 2009;64:101-6.
11. Hendler I, Schatz M, Momirova V, et al. Association of obesity with pulmonary and nonpulmonary complications of pregnancy in asthmatic women. *Obstet Gynecol* 2006;108:77-82.
12. Bertrand J-M, Riley SP, Popkin J, Coates AL. The long-term pulmonary sequelae of prematurity: the role of familial airway hyperactivity and the respiratory distress syndrome. *N Engl J Med* 1985;312:742-5.
13. Riedel F, Achenbach U, Rieger CHL. Prematurity and maternal bronchial hyperresponsiveness. *J Perinat Med* 1989;17:151-5.
14. Siddiqui S, Goodman N, McKenna S, Goldie M, Waugh J, Brightling CE. Pre-eclampsia is associated with airway hyperresponsiveness. *BJOG* 2008;115:520-2.
15. Schatz M, Zeiger RS, Hoffman CP. Intrauterine growth is related to gestational pulmonary function in pregnant asthmatic women. *Chest* 1990;98:389-92.
16. Bracken MB, Triche EW, Belanger K, Saflas A, Beckett WS, Leaderer BP. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. *Obstet Gynecol* 2003;102:739-52.
17. Bakhireva LN, Schatz M, Jones KL, Chambers CD. Asthma control during pregnancy and the risk of preterm delivery or impaired fetal growth. *Ann Allergy Asthma Immunol* 2008;101:137-43.
18. Schatz M, Dombrowski MP, Wise R, et al. Spirometry is related to perinatal outcomes in pregnant women with asthma. *Am J Obstet Gynecol* 2006;194:120-6.
19. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. *Thorax* 2006;61:169-76.
20. Gluck JC, Gluck PA. The effect of pregnancy on the course of asthma. *Immunol Allergy Clin North Am* 2006;26:63-80.
21. Schatz M, Dombrowski MP, Wise R, et al. Asthma morbidity during pregnancy can be predicted by severity classification. *J Allergy Clin Immunol* 2003;112:283-8.
22. National Asthma Education Program report of the Working Group on Asthma and Pregnancy: management of asthma during pregnancy. Bethesda, MD: National Heart, Lung, and Blood Institute, September 1993. (NIH publication no. 93-3279.)
23. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. *Obstet Gynecol* 2008;111:457-64.
24. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma: full report 2007. (Accessed April 6, 2009, at <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf>.)
25. NAEPP expert panel report: managing asthma during pregnancy: recommendations for pharmacologic treatment — 2004 update. *J Allergy Clin Immunol* 2005;115:34-46. [Erratum, *J Allergy Clin Immunol* 2005;115:477.]
26. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. *J Allergy Clin Immunol* 2004;114:1288-93.
27. Enriquez R, Wu P, Griffin MR, et al. Cessation of asthma medication in early pregnancy. *Am J Obstet Gynecol* 2006;195:149-53.
28. Chambers K. Asthma education and outcomes for women of childbearing age. *Case Manager* 2003;14:58-61.
29. Murphy VE, Gibson P, Talbot PI, Clifton VL. Severe asthma exacerbations during pregnancy. *Obstet Gynecol* 2005;106:1046-54.
30. Dombrowski MP, Schatz M, Wise R, et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. *Am J Obstet Gynecol* 2004;190:737-44.
31. Wendel PJ, Ramin SM, Barnett-Hamm X, Rowe TF, Cunningham FG. Asthma

- treatment in pregnancy: a randomized controlled trial. *Am J Obstet Gynecol* 1996;175:150-4.
32. Schatz M, Zeiger RS, Harden K, Hoffman CC, Chilingar L, Petitti D. The safety of asthma and allergy medications during pregnancy. *J Allergy Clin Immunol* 1997; 100:301-6.
 33. Schatz M, Dombrowski MP, Wise R, et al. The relationship of asthma medication use to perinatal outcomes. *J Allergy Clin Immunol* 2004;113:1040-5.
 34. Martel M-J, Rey E, Beauchesne M-F, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy-induced hypertension: nested case-control study. *BMJ* 2005;330:230-6.
 35. Bakhireva LN, Jones KL, Schatz M, et al. Asthma medication use in pregnancy and fetal growth. *J Allergy Clin Immunol* 2005;116:503-9.
 36. Martel M-J, Rey E, Beauchesne M-F, et al. Use of short-acting β_2 -agonists during pregnancy and the risk of pregnancy-induced hypertension. *J Allergy Clin Immunol* 2007;119:576-82.
 37. Källén B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. *Obstet Gynecol* 1999;93:392-5.
 38. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. *J Allergy Clin Immunol* 2003;111:736-42.
 39. Lin S, Munsie JPW, Herdt-Losavio ML, et al. Maternal asthma medication use and the risk of gastroschisis. *Am J Epidemiol* 2008;168:73-9.
 40. Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. *J Allergy Clin Immunol* 2008;121:1379-84.
 41. Stothard KJ, Tennant PWG, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. *JAMA* 2009;301:636-50.
 42. Yang J, Carmichael SL, Canfield M, Song J, Shaw GM. Socioeconomic status in relation to selected birth defects in a large multicentered US case-control study. *Am J Epidemiol* 2008;167:145-54.
 43. Bakhireva LN, Jones KL, Schatz M, et al. Safety of leukotriene receptor antagonists in pregnancy. *J Allergy Clin Immunol* 2007;119:618-25.
 44. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting β -agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. *Am J Respir Crit Care Med* 2008;178:1009-16.
 45. Nelson HS, Carr W, Nathan R, Portnoy JM. Update on the safety of long-acting β -agonists in combination with inhaled corticosteroids for the treatment of asthma. *Ann Allergy Asthma Immunol* 2009;102:11-5.
 46. Towers CV, Briggs GG, Rojas JA. The use of prostaglandin E2 in pregnant patients with asthma. *Am J Obstet Gynecol* 2004;190:1777-80.
 47. Hägerdal M, Morgan CW, Sumner AE, Gutsche BB. Minute ventilation and oxygen consumption during labor with epidural analgesia. *Anesthesiology* 1983;59:425-7.
 48. Schatz M, Zeiger RS, Hoffman CP, et al. Perinatal outcomes in the pregnancies of asthmatic women: a prospective controlled analysis. *Am J Respir Crit Care Med* 1995;151:1170-4.
 49. Stenius-Aarniala BSM, Hedman J, Teramo KA. Acute asthma during pregnancy. *Thorax* 1996;51:411-4.
 50. Dombrowski MP, Schatz M, Wise R, et al. Asthma during pregnancy. *Obstet Gynecol* 2004;103:5-12.

Copyright © 2009 Massachusetts Medical Society.

COLLECTIONS OF ARTICLES ON THE JOURNAL'S WEB SITE

The *Journal's* Web site (NEJM.org) sorts published articles into more than 50 distinct clinical collections, which can be used as convenient entry points to clinical content. In each collection, articles are cited in reverse chronologic order, with the most recent first.